Original from: 360DX

Digital pathology firm Paige said Thursday it has forged a partnership with Ohio State University's Wexner Medical Center for a study to evaluate the use of artificial intelligence-assisted tools to diagnose prostate cancer in a community hospital setting.

The clinical utility and health economics study will measure the accuracy and efficiency of the Paige Prostate Suite including how the AI-assisted workflow affects the time, resource use, and cost of diagnoses. The retrospective study is intended to compare differences in prostate cancer detection, grading, and quantification between pathologists who use the algorithm-driven Paige Prostate Suite and subspecialists who develop diagnoses without those tools.

"The study by OSWMC and its affiliates using Paige will provide greater insight into the impact AI has on their diagnostic capabilities and ultimately help pathologists and oncologists feel confident in the accuracy and efficiency of AI to support them in detecting, diagnosing and treating prostate cancer patients," Paige Co-Founder and Chief Medical Officer David Klimstra said in a statement.

Swati Satturwar, clinical assistant professor of pathology at OSU and the study's principal investigator, said the study will "showcase the effectiveness of AI in the community setting and will provide real-life evidence to enhance adoption of AI for routine clinical use."

Source: Paige, Ohio State Form Research Collaboration on AI-Driven Prostate Cancer Diagnosis